Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 970-976

  Kirkpatrick, William R ^a,b   Najvar, Laura K ^a,b   Vallor, Ana C ^a,c   Wiederhold, Nathan P ^a,d   Bocanegra, Rosie ^a,b   Pfeiffer, Juergen ^e   Perkins, Kimberly ^e   Kugler, Alan R ^e,f   Sweeney, Theresa D ^e   Patterson, Thomas F ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF THE INCARNATE WORD   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e NEKTAR THERAPEUTICS   (United States)

^f Coastal Pharma Group ^*  (United States)

Author keywords

ABIP; Animal model; Aspergillus; Prophylaxis

Indexed keywords

AMPHOTERICIN B; CEFTAZIDIME; CORTISONE ACETATE; CYCLOPHOSPHAMIDE; TOBRAMYCIN; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; COLONY FORMING UNIT; CONIDIUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRY POWDER; EXPERIMENTAL GUINEA PIG; IMMUNE DEFICIENCY; INFECTION PREVENTION; LUNG ASPERGILLOSIS; LUNG PARENCHYMA; MALE; NONHUMAN; PATHOGEN LOAD; POLYMERASE CHAIN REACTION; POWDER INHALER; QUANTITATIVE ASSAY; SINGLE DRUG DOSE; SURVIVAL RATE;

ADMINISTRATION, INHALATION; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CHEMOPREVENTION; COLONY COUNT, MICROBIAL; CORTISONE; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; GUINEA PIGS; IMMUNOSUPPRESSIVE AGENTS; INVASIVE PULMONARY ASPERGILLOSIS; LUNG; MALE; PYRIMIDINES; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 84858666186     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr567     Document Type: Article

References (36)

1. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013-25.
2. Baddley JW, Stroud TP, Salzman D et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-24.
3. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
4. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-47.
5. Morris G, Kokki MH, Anderson K et al. Sampling of Aspergillus spores in air. J Hosp Infect 2000; 44: 81-92.
6. Kugler AR, Sweeney TD, Eldon MA. Prophylaxis of invasive aspergillosis in neutropenic rabbits using an inhaled, novel, dry-powder amphotericin B formulation. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract LB2-31, late breaker supplement. American Society for Microbiology, Washington, DC, USA.
7. Kugler AR, Sweeney TD, Lalonde G et al. Prophylactic administration of amphotericin B inhalation powder (ABIP) prolongs survival of neutropenic rabbits inoculated with Aspergillus. In: Abstracts of the Second Meeting of Advances Against Aspergillosis, Athens, Greece, 2006. Abstract P111, pp. 206-7. The Foundation for Infectious Diseases, Saratoga, CA, USA.
8. Kugler AR, Lee JD, Samford LK et al. Amphotericin B inhalation powder (ABIP) achieves significant pulmonary and low systemic amphotericin B concentrations. In: Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology, Paris, France, 2006. Abstract O-0011. The International Society for Human and Animal Mycology.
9. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi-Second Edition: Approved Standard M38A2. CLSI, Wayne, PA, USA, 2008.
11. Wiederhold NP, Najvar LK, Vallor AC et al. Assessment of serum (1→3)-β-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2008; 52: 1176-8.
12. Vallor AC, Kirkpatrick WR, Najvar LK et al. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother 2008; 52: 2593-8.
13. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academies Press, 2010.
14. Raabe OG, Yeh HC, Newton GJ et al. Deposition of inhaled monodisperse aerosols in small rodents. In: Walton WH, ed. Inhaled Particles IV. Oxford: Pergamon Press, 1977; 3-20.
15. Bowman JC, Abruzzo GK, Anderson JW et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474-81.
16. Costa C, Vidaud D, Olivi M et al. Development of two real-time quantitative TaqMan PCR assays to detect circulating Aspergillus fumigatus DNA in serum. J Microbiol Methods 2001; 44: 263-9.
17. Jin J, Lee YK, Wickes BL. Simple chemical extraction method for DNA isolation from Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 2004; 42: 4293-6.
18. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
19. Pickering JW, Sant HW, Bowles CA et al. Evaluation of a (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-62.
20. Marr KA, Laverdiere M, Gugel A et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-9.
21. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
22. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.
23. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
24. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-9.
25. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
26. Allen SD, Sorensen KN, Nejdl MJ et al. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994; 34: 1001-13.
27. Ruijgrok EJ, Vulto AG, Van Etten EW. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 2001; 48: 89-95.
28. Gavaldà J, Martín MT, López P et al. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 2005; 49: 3028-30.
29. Rijnders BJ, Cornelissen JJ, Slobbe L et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401-8.
30. Dummer JS, Lazariashvilli N, Barnes J et al. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004; 23: 1376-81.
31. Drew RH, Dodds Ashley E, Benjamin DK Jr et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232-7.
32. Weickert MJ. Recent clinical findings with applications of amphotericin B variants: inhalation powder. In: Abstracts of Focus on Fungal Infections 16, Las Vegas, NV, 2006. Abstract p. 99.
33. Alexander BD, Dodds Ashley ES, Addison RM et al. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006; 8: 13-20.
34. Bekersky I, Fielding RM, Dressler DE et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46: 834-40.
35. Lewis RE, Wiederhold NP, Prince RA et al. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. J Antimicrob Chemother 2006; 57: 288-93.
36. Christiansen KJ, Bernard EM, Gold JW et al. Distribution and activity of amphotericin B in humans. J Infect Dis 1985; 152: 1037-43.